Edgewise Therapeutics (EWTX) Competitors $30.78 -0.02 (-0.06%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EWTX vs. RDY, SRPT, CTLT, PCVX, QGEN, ITCI, ROIV, ASND, RVMD, and LNTHShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Vaxcyte (PCVX), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Edgewise Therapeutics (NASDAQ:EWTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking. Do insiders and institutionals hold more shares of EWTX or RDY? 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 24.1% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, EWTX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$100.16M-$1.50-20.52Dr. Reddy's Laboratories$299.87B0.04$668M$0.6324.40 Does the MarketBeat Community favor EWTX or RDY? Dr. Reddy's Laboratories received 287 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. However, 73.91% of users gave Edgewise Therapeutics an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformEdgewise TherapeuticsOutperform Votes3473.91% Underperform Votes1226.09% Dr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Do analysts recommend EWTX or RDY? Edgewise Therapeutics currently has a consensus price target of $43.17, indicating a potential upside of 40.24%. Dr. Reddy's Laboratories has a consensus price target of $17.00, indicating a potential upside of 10.61%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Edgewise Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is EWTX or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 17.81% compared to Edgewise Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 18.53% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -26.83% -25.67% Dr. Reddy's Laboratories 17.81%18.53%13.01% Which has more volatility and risk, EWTX or RDY? Edgewise Therapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Does the media favor EWTX or RDY? In the previous week, Edgewise Therapeutics had 15 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 20 mentions for Edgewise Therapeutics and 5 mentions for Dr. Reddy's Laboratories. Edgewise Therapeutics' average media sentiment score of 0.72 beat Dr. Reddy's Laboratories' score of 0.58 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDr. Reddy's Laboratories beats Edgewise Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.91B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-20.5210.5991.3417.19Price / SalesN/A195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book6.795.104.794.78Net Income-$100.16M$151.51M$120.07M$225.60M7 Day Performance11.44%-2.15%-1.90%-1.23%1 Month Performance-4.10%-3.14%11.45%3.37%1 Year Performance234.93%11.50%30.63%16.58% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics2.7304 of 5 stars$30.78-0.1%$43.17+40.2%+261.7%$2.91BN/A-20.5260Analyst ForecastAnalyst RevisionRDYDr. Reddy's Laboratories1.8548 of 5 stars$14.74+1.9%$17.00+15.3%+15.8%$12.30B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8116 of 5 stars$126.42+2.2%$178.71+41.4%+31.8%$12.08B$1.64B98.971,314Analyst ForecastCTLTCatalent2.7788 of 5 stars$63.47+0.6%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.6049 of 5 stars$90.37+3.0%$147.50+63.2%+45.4%$11.26BN/A-19.07160Analyst ForecastInsider TradeQGENQiagen3.7415 of 5 stars$45.46+0.1%$51.15+12.5%+3.1%$10.37B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0406 of 5 stars$84.70+2.0%$97.23+14.8%+27.8%$8.98B$612.78M-95.91560ROIVRoivant Sciences3.0418 of 5 stars$12.07+1.9%$17.93+48.5%+16.2%$8.79B$129.13M2.10860Insider TradeASNDAscendis Pharma A/S3.128 of 5 stars$135.89+4.6%$191.77+41.1%+12.6%$8.24B$327.43M-16.52640RVMDRevolution Medicines4.5467 of 5 stars$44.93-0.2%$63.67+41.7%+71.5%$7.56B$11.58M-12.54443Insider TradeLNTHLantheus4.3768 of 5 stars$94.77+1.9%$130.00+37.2%+53.4%$6.59B$1.50B15.42834Analyst Forecast Related Companies and Tools Related Companies Dr. Reddy's Laboratories Competitors Sarepta Therapeutics Competitors Catalent Competitors Vaxcyte Competitors Qiagen Competitors Intra-Cellular Therapies Competitors Roivant Sciences Competitors Ascendis Pharma A/S Competitors Revolution Medicines Competitors Lantheus Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EWTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
